clinical trial · NCT06843967
A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma
Well Differentiated LiposarcomaDedifferentiated LiposarcomaLiposarcomaMyxoid LiposarcomaRound Cell LiposarcomaMyxoid Pleomorphic LiposarcomaPleomorphic LiposarcomaUnresectable LiposarcomaMirdametinibPalbociclib
brief summary
The purpose of this study is to find out whether mirdametinib in combination with palbociclib is an effective and safe treatment for people with metastatic, recurrent, and unresectable liposarcoma. This study will test different doses of mirdametinib in combination with a fixed dose of palbociclib to find the best safe dose for further testing.
started
Feb 19, 2025
primary completion
Aug 19, 2028
completion
Aug 19, 2028
last updated
Mar 13, 2026
official title
A Phase Ib/II Study of the Mirdametinib in Combination With Palbociclib in Patients With Advanced Dedifferentiated Liposarcoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol